Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen

The clinical translation of theranostic (177)Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges still remain, particularly regarding their pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpanese, Debora, Ferro-Flores, Guillermina, Ocampo-Garcia, Blanca, Santos-Cuevas, Clara, Salvarese, Nicola, Figini, Mariangela, Fracasso, Giulio, De Nardo, Laura, Bolzati, Cristina, Rosato, Antonio, Meléndez-Alafort, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283306/
https://www.ncbi.nlm.nih.gov/pubmed/32518372
http://dx.doi.org/10.1038/s41598-020-66285-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283306/
https://www.ncbi.nlm.nih.gov/pubmed/32518372
http://dx.doi.org/10.1038/s41598-020-66285-2

Ejemplares similares